A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

  • End date
    Dec 6, 2028
  • participants needed
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 16 December 2021
growth factor
epidermal growth factor receptor
epidermal growth factor
breast carcinoma
her2/neu-positive breast cancer


The goal of this study is to evaluate the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in participants with unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with taxane anti-cancer agent, trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1). The primary hypothesis is that the confirmed objective response rate (cORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as determined by independent central review (ICR) for the combination of tucatinib, trastuzumab and capecitabine, is greater than 20%.

Condition Breast Cancer
Treatment Capecitabine, Trastuzumab, Tucatinib
Clinical Study IdentifierNCT04721977
SponsorMerck Sharp & Dohme Corp.
Last Modified on16 December 2021


Yes No Not Sure

Inclusion Criteria

Has histologically confirmed HER2+ breast carcinoma
Has received previous treatment with taxane anti-cancer agent, trastuzumab, pertuzumab, and T-DM1 with the exception of when the use of taxanes is contraindicated or judged not to be the best treatment at the investigator's discretion
Has radiographically and/or histologically confirmed disease progression on last systemic anticancer treatment
Has adequate organ function
Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP and using contraception or abstinent from heterosexual intercourse during the intervention period and for at least 30 days after receiving the last dose of tucatinib, 80 days after receiving the last dose of trastuzumab, or 180 days after receiving the last dose of capecitabine, whichever occurs last and agrees to not donate eggs during this period
Male participants refrain from donating sperm and are either abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after receiving the last dose of tucatinib and 90 days after receiving the last dose of capecitabine, whichever occurs last
Previously treated brain metastasis is stable or progressed, provided there is no clinical indication for immediate re-treatment

Exclusion Criteria

Has been previously treated with lapatinib within 12 months of starting study treatment
Has been previously treated with neratinib, afatinib, tucatinib or capecitabine
Has a history of exposure to doxorubicin, epirubicin, mitoxantrone, idarubicin, liposomal doxorubicin
Has had treatment with any systemic anti-cancer therapy including hormonal therapy, non-central nervous system (CNS) radiation or experimental agent ≤3 weeks before first dose of study treatment
Has any toxicity related to prior cancer therapies that has not resolved with the exception of alopecia, congestive heart failure, anemia
Has clinically significant cardiopulmonary disease
Has known myocardial infarction or unstable angina within 6 months prior to the first dose of study treatment
Has any uncontrolled viral, bacterial or fungal infection within 14 days prior to the first dose of study treatment
Is positive for Hepatitis B, Hepatitis C or has known chronic liver disease
Is known to be positive for human immunodeficiency virus (HIV)
Has evidence within 2 years of the start of study treatment of another malignancy that required systemic treatment
Has ongoing use of systemic corticosteroids for control of symptoms of brain metastases
Has any brain lesion thought to require immediate local therapy
Has known or suspected leptomeningeal disease (LMD)
Has poorly controlled generalized or complex partial seizures or manifest neurologic progression due to brain metastases
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note